Free Trial
NASDAQ:PMCB

Nuvilex 3/18/2024 Earnings Report

Nuvilex logo
$0.83 -0.02 (-2.35%)
Closing price 08/8/2025 03:47 PM Eastern
Extended Trading
$0.86 +0.03 (+3.49%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvilex EPS Results

Actual EPS
-$0.65
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvilex Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Nuvilex Earnings Headlines

MyMD Pharmaceuticals Secures Strategic Investments
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
PharmaCyte Biotech Inc PMCB
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex (NASDAQ:PMCB), Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View Nuvilex Profile

More Earnings Resources from MarketBeat